Q2 CY26
Quarterly Report

31 July 2026

ASX:OSX

Quarterly highlights

Osteopore Limited (ASX:OSX) ("**Osteopore**" or the "**Company**"), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to release its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 30 June 2026.

Osteopore captures revenue of AUD 676k for Q2 CY26

Q2 CY26 is slightly below expectations due to slow uptake of custom-made cranioplasty and ongoing distribution transitions in Europe.

OSX secures Hainan FDA approval for orthopaedic devices

OSX secures Hainan FDA approval for its orthopaedic custom device in collaboration with Shanghai Ruijin Hospital

OSX orthopaedic products gain Malaysian market access rights

OSX orthopaedic product line continues with regional market expansion into Malaysia

Quarterly highlights

Osteopore Limited (ASX:OSX) ("**Osteopore**" or the "**Company**"), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to release its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 30 June 2026.

OSX neuro products approved in a major centre in Thailand

Our neurosurgery product line gains approval at Thammasat University Hospital following the change in distribution partners

OSX & DKSH Malaysia dental launch; First products delivered

OSX & DKSH prepare to launch dental regenerative products with the first delivery of products.

First OSX custom implant completed in Hong Kong

OSX successfully treats the first patient after appointing its distributor for Hong Kong, and records the first collaboration with the Tam Shiu Anatomical Modelling Lab

Quarterly highlights

Osteopore Limited (ASX:OSX) ("**Osteopore**" or the "**Company**"), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to release its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 30 June 2026.

OSX & QCH launch trial for nasoalveolar augment in children

Recruitment is completed and the first two patients had been treated

First patient treated in OSX-PAH jaw reconstruction trial

The first patient has been successfully treated with a custom jaw implant.

Our quarterly revenue performance in Q2 2026 was slightly below our expectations mostly due to the slow uptake of our custom-made cranial reconstruction device in Europe driven by a slightly longer period of verifying clinical outcomes, thereby lengthening the sales cycle. Apart from this, there are still ongoing distribution transitions in the region.

Nonetheless, we are pleased to observe progress in several activities in this quarter, especially in clinical trials. The cleft lip augmentation study performed at the Queensland Children's Hospital has completed patient recruitment, along with the treatment of the first 2 patients. In addition, the jaw reconstruction clinical trial at the Princess Alexandra Hospital has also successfully commenced.

Our market access and expansion activities have now brought our orthopaedic product line into Malaysia and Hainan, with Hong Kong also having completed the first customised orthopaedic implant. In addition, our neurosurgery product line has now received product listing approval in Thammasat University Hospital, a major centre in Thailand.

Mark Leong
Executive Chairman

Osteopore reports AUD 676K (~SGD 614K) revenue for Q2 CY26, down from prior period



***A$/S$:** Average exchange rate of each quarter is obtained from https://www.rba.gov.au/



OSX orthopaedic products gain Malaysian market access rights

- On 15 May 2026 [1], Regulatory access granted in Malaysia for Osteopore's orthopaedic portfolio, including the Company's centerpiece high tibial osteotomy (HTO) solution and other bone grafting applications.
- As the implants are produced from biomaterials (not from cadaveric or animal sources), they offer an option that aligns with considerations important to Muslim patients.
- Osteopore will now establish commercial representation and begin customer engagement activities in Malaysia.
- In 2025, the Malaysian bone graft and substitute market valuation was approximately USD 250-300m (AUD 360-465m). It is expected to grow at a compound annual growth rate (CAGR) of 7-9% over the next 2 years [2].

1 ASX announcement: 'OSX orthopaedic products gain Malaysian market access rights', 15 May 2026

2 https://www.marketsizeandtrends.com/report/bone-graft-and-substitute-market/



OSX secures Hainan FDA approval for orthopaedic devices

- On 26 May 2026 [1], Osteopore received approval from the Hainan Medical Products Administration (Hainan FDA) for the clinical use of its orthopaedic custom medical devices at the Hainan branch hospital of the prestigious Shanghai Ruijin Hospital, located within the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
- The Hainan Boao Lecheng International Medical Tourism Pilot Zone is China's strategic and only special medical zone, benefitting from preferential national-level policies that allows innovative medical technologies and devices to be used clinically prior to receiving full mainland approval.
- The China orthopaedic devices market was valued at USD 2.5 billion (AUD 3.5 billion) in 2024, and is projected to reach USD 4.5 billion (AUD 6.4 billion) by 2035, at a CAGR of 5.6% [2].

1 ASX announcement: 'OSX secures Hainan FDA approval for orthopaedic devices', 26 May 2026

2 https://www.marketresearchfuture.com/reports/china-orthopedic-devices-market-44863

OSX & QCH launch trial for nasoalveolar augment in children, treats first 2 patients

- On 2 June 2026 [1], Osteopore and Queensland Children's Hospital (QCH) launched a clinical trial for paranasal augmentation in 5 paediatric patients with unilateral (one-sided) cleft lip – which is the augmentation of the nose and surrounding upper jaw structure.
- On 26 June 2026 [2], all 5 patients were recruited to the trial.
- On 29 June 2026 [3], the first 2 patients were treated.
- Cleft lip and palate affects approximately 1 in 1,000 births globally [4], making it one of the most prevalent congenital conditions worldwide.
- The global cleft lip and palate repair market was valued at approximately USD 1.2b (~AUD 1.7b) in 2024 and is forecast to reach USD 1.9b (~AUD 2.7b) by 2033, growing at a CAGR of 5.5% [5].

1 ASX announcement: 'OSX & QCH launch trial for nasoalveolar augment in children', 2 June 2026
2 ASX announcement: 'QCH cleft lip study patient recruitment completed', 26 June 2026
3 ASX announcement: 'First 2 patients treated in QCH cleft lip clinical trial', 29 June 2026

4 DOI: 10.15761/OHNS.1000246
5 https://www.verifiedmarketreports.com/product/cleft-lip-and-palate-repair-market/



OSX & DKSH Malaysia dental launch; First products delivered

- On 17 June 2026 [1], Osteopore announced the first delivery of dental products following the signing of a five year partnership with DKSH Malaysia Sdn Bhd, a subsidiary of DKSH Holding Ltd (SIX:DKSH).
- As previously announced on 25 November 2025 [2], Osteopore entered into a five-year agreement with DKSH for the distribution of its dental product portfolio in Malaysia.
- The first product delivery marks an important milestone in the execution of the partnership and the commercial expansion of Osteopore's dental business in the Malaysian market.

1 ASX announcement: 'OSX & DKSH Malaysia dental launch First products delivered', 17 June 2026
2 ASX announcement: 'OSX partners DKSH for dental products in Malaysia', 25 November 2025

First OSX custom orthopaedic implant completed in Hong Kong

- On 22 June 2026 [1], Osteopore announced the completion of the first orthopaedic reconstruction case in Hong Kong.
- The surgery, a correction of deformity at the patient's wrist, was performed at Queen Mary Hospital by Clinical Associate Professor Christian Fang Xinshuo, who is also leading efforts at the Tam Shiu Anatomical Modelling Laboratory.
- This also marks the first collaboration milestone between Osteopore and the Tam Shiu Anatomical Modelling Laboratory.
- Although Hong Kong is a relatively small market, it holds strategic importance to China as a potential gateway to the Greater Bay Area. The potential benefits include regulatory harmonisation initiatives that facilitate cross-border use of medical devices and collaborative innovation across the region's extensive healthcare infrastructure [2].

1 ASX announcement: 'First OSX custom orthopaedic implant completed in Hong Kong', 22 June 2026

2 https://www.bayarea.gov.hk/gbais/tc/development/medical-co-operation/allowing-designated-healthcare-institutions-in-the-greater-bay-area-to-use-hong-kong-registered-drugs-and-medical-devices/



OSX neuro products approved in a major centre in Thailand

- On 24 June 2026 [1], Osteopore announced that its neurosurgery products have been approved for use in a major medical centre in Bangkok, Thailand – Thammasat University Hospital.
- This positive development follows the appointment of Peakmed Co., Ltd (Peakmed) as Osteopore's exclusive distributor in Thailand, as announced on 6 May 2025 [2].
- Thammasat University Hospital (TUH) is a teaching hospital with more than 1,500 outpatients a day and has more than 800 beds for inpatient care [3].
- Thailand's craniomaxillofacial (CMF) market is a primary focus for Osteopore due to the significant number of neurosurgical procedures. Neurosurgery is a one segment within the broader CMF market.

1 ASX announcement: 'OSX neuro products approved in a major centre in Thailand', 24 June 2026
2 ASX announcement: 'Osteopore strengthens Thailand craniofacial distribution', 6 May 2025

3 https://en.wikipedia.org/wiki/Thammasat_University_Hospital

First patient treated in OSX-PAH jaw reconstruction trial

- On 30 June 2026 [1], Osteopore announced that the first patient for the jaw reconstruction clinical trial, conducted at the Princess Alexandra Hospital (PAH), has been successfully treated with Osteopore's novel implant.
- As previously announced on 4 June 2025 [2] and 21 July 2025 [3], Osteopore and Princess Alexandra Hospital (PAH) were given approval to commence a jawbone reconstruction clinical trial with Osteopore's novel implant.
- The single-arm feasibility study aims to recruit at least 10 adult patients in Australia by 2028. Each patient will be assessed 36 months post-surgery.

1 ASX announcement: 'First patient treated in OSX-PAH jaw reconstruction trial', 30 June 2026
2 ASX announcement: 'Osteopore launches clinical study for jawbone reconstruction', 4 June 2025
3 ASX announcement: 'Jaw recon trial approved, first patient to be recruited', 21 July 2025

Professional society engagement

36th Annual Conference, The Oculoplastic Association of India meeting, April 2026

At this meeting, our product for orbital reconstruction was featured prominently in many independent sessions, with surgeons presenting clinical evidence of bone formation after 2 years. Our CEO, Dr. Lim Yujing, was also invited to speak at a 3D printing session to share how Osteopore utilises 3D printing in medicine and surgery.



Principles of Flap Design & Bone Grafting in Regenerative Dental Surgery, May 2026

Osteopore sponsored the 2nd edition workshop, which was part of the NUS Dentistry-NUCOHS Clinical Dentistry & Research Symposium. Participants were trained on the principles of flap design when using the Osteomesh, and caught a glimpse of the chairside dentin graft technology, which Osteopore had secured distribution rights for in 2026.

Appendix 4C - Quarterly cashflow report

Corporate and financial summary

The attached Appendix 4C provides details of the cashflows for the quarter ended 30 June 2026.

As at 30 June 2026, the Company has a cash balance of approximately A$1,255,000.

Net cash used in operating activities during the quarter amounted to approximately A$691,000. This was higher compared to the previous quarter, which had received a one-off receipt of the RMB2.5 million (~A$565,000) dossier fee from Majeton Pte Ltd as part of the key terms for the commercialisation of products in China, Hong Kong, and Macau. Excluding this one-off item, net cash used in operating activities was broadly consistent with the recent quarters.

The Company maintains access to the redeemable convertible note facility with an aggregate nominal value of up to A$20,000,000, of which A$6,000,000 had been drawn as at 30 June 2026, leaving A$14,000,000 in available funding.

Related party transactions

Payments in the June quarter to related parties of approximately A$174,000 at Item 6 in Appendix 4C, comprised of director fees and salaries.

This presentation has been authorised and approved in accordance with the Company's published continuous disclosure policy and has been approved by the Board.

Osteopore®

Mark Leong
Executive Chairman
E: mark_leong@osteopore.com

Lim Yujing PhD
Chief Executive Officer & Chief Technology Officer
E: lim_yujing@osteopore.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Osteopore Limited

ABN	**Quarter ended ("current quarter")**
65 630 538 957	30 June 2026

Consolidated statement of cash flows			**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**			
1.1	Receipts from customers		584	1,199
1.2	Payments for			
	(a)	research and development	(91)	(160)
	(b)	product manufacturing and operating costs	(283)	(523)
	(c)	marketing, business development & investor relations (including allocated staff costs)	(327)	(736)
	(d)	leased assets	(28)	(58)
	(e)	staff costs (other than allocated staff costs under note 1.2(c))	(388)	(754)
	(f)	administration and corporate costs	(238)	(567)
1.3	Dividends received (see note 3)		-	-
1.4	Interest received		2	3
1.5	Interest and other costs of finance paid		-	(1)
1.6	Income taxes paid		4	4
1.7	Government grants and tax incentives		74	132
1.8	Other (dossier fee)		-	565
1.9	**Net cash from / (used in) operating activities**		**(691)**	**(896)**

2.	**Cash flows from investing activities**			
2.1	Payments to acquire:			
	(a)	entities	-	-
	(b)	businesses	-	-
	(c)	property, plant and equipment	(7)	(37)

	Consolidated statement of cash flows	Current quarter $A'000	Year to date (6 months) $A'000
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	(45)
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	**Net cash from / (used in) investing activities**	**(7)**	**(82)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	250	1,750
3.3	Proceeds from exercise of share options	1	1
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(15)	(105)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	**Net cash from / (used in) financing activities**	**236**	**1,646**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,734	627

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(691)	(896)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(7)	(82)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	236	1,646
4.5	Effect of movement in exchange rates on cash held	(17)	(40)
4.6	**Cash and cash equivalents at end of period**	**1,255**	**1,255**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	1,249	1,728
5.2	Call deposits	6	6
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,255**	**1,734**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	174
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Payments made to Directors related to:

1. Non-executive director fees and superannuation;
2. Executive director fees and salaries

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	20,000	6,000
7.4	**Total financing facilities**	**20,000**	**6,000**
7.5	**Unused financing facilities available at quarter end**		**14,000**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

On 24 December 2024, the Company entered into a subscription agreement to issue 4% redeemable convertible notes with an aggregate nominal value of up to $20,000,000 comprising of 4 equal tranches of nominal value of $5,000,000 each. Each tranche comprises 20 equal sub-tranches of $250,000 each. The face value of the convertible notes when issued is $50,000 each.

The interest amount is equivalent to 100% of the nominal value of the convertible notes at the rate of 4.0% per annum. The interest is payable in cash quarterly in arrears.

The maturity date of the notes is 36 months from the closing date of the first tranche. A Noteholder may at any time up to 7 calendar days prior to the maturity date exercise its right to convert all outstanding notes into shares. The convertible notes which are not redeemed or purchased, converted or cancelled by the Company on or before the maturity date shall be converted by the Company on the maturity date.

The conversion price shall be 80% of the average of the closing price per share on any 5 consecutive business days as selected by the noteholder during the 45 business days immediately preceding the relevant Conversion Date on which shares were traded on the ASX.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(691)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	1,255
8.3	Unused finance facilities available at quarter end (Item 7.5)	14,000
8.4	Total available funding (Item 8.2 + Item 8.3)	15,255
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	**22.08**

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: NA

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: NA

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: NA

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Authorised by: By the Board

....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g., Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.